Physician profile
Douglas D Zhang
NPI 1023074341
$20,053.84
in general payments reported to CMS, 2019-2025
54 companies · $1,427 in 2025
The $1,427 reported for 2025 was more than what 94% of Geriatric Medicine (Family Medicine) providers received nationally (typical 2025 total: $119).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,977 · 2020: $3,659 · 2021: $3,660 · 2022: $3,288 · 2023: $2,431 · 2024: $1,612 · 2025: $1,427.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,452 · Education: $17.44.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,452.03 |
| Education | $17.44 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,354.88 | 2019-2025 | Vraylar, Creon |
| Novo Nordisk INC | $2,142.19 | 2019-2025 | Ozempic, Rybelsus |
| Glaxosmithkline, LLC. | $2,066.17 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Janssen Pharmaceuticals, INC | $1,543.98 | 2019-2024 | Xarelto |
| Astrazeneca Pharmaceuticals Lp | $1,470.90 | 2019-2025 | Farxiga, Breztri, Airsupra |
| Lilly USA, LLC | $903.65 | 2019-2025 | Mounjaro, Jardiance |
| Boehringer Ingelheim Pharmaceuticals, INC. | $830.76 | 2019-2025 | Jardiance, Tradjenta |
| Pfizer INC. | $735.49 | 2019-2024 | |
| Mylan Specialty L.P. | $617.87 | 2019-2024 | Yupelri |
| Teva Pharmaceuticals USA, INC. | $567.65 | 2019-2022 | |
| Amgen INC. | $501.39 | 2019-2024 | Otezla, Repatha, Krystexxa |
| Merck Sharp & Dohme LLC | $485.51 | 2019-2025 | Gardasil 9, Capvaxive, Gardasil |
| Amarin Pharma, INC. | $462.67 | 2019-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $447.08 | 2021-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $422.42 | 2019-2023 | Xifaxan |
Show all 54 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Douglas Zhang listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.